

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康臣藥業集團有限公司
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1681)

SUPPLEMENTAL ANNOUNCEMENT TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2018 AND THE INTERIM REPORT FOR THE SIX MONTHS ENDED 30 JUNE 2019

References are made to (i) the announcements of the Consun Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 24 October 2017 and 3 November 2017 in relation to the placing of new shares under general mandate (the “**Placing Announcements**”); (ii) the interim report for the six months ended 30 June 2018 published by the Company on 20 September 2018 (the “**2018 Interim Report**”); (iii) the annual report for the year ended 31 December 2018 published by the Company on 30 April 2019 (the “**2018 Annual Report**”); and (iv) the interim report for the six months ended 30 June 2019 published by the Company on 6 September 2019 (the “**2019 Interim Report**”). Unless otherwise stated, capitalised terms used herein shall have the same meanings as those defined in the Placing Announcements.

As disclosed in the 2018 Interim Report, among the net proceeds of approximately HKD284,439,000 raised from the Placing, approximately HKD98,000,000 had been used for repayment of bank loans and the remaining approximately HKD186,439,000 had not been used up as at 30 June 2018. The Company planned to use the remaining approximately HKD186,439,000 for repayment of bank loans within 18 months subject to the identification of future investment opportunities of the Group (as and when opportunities arise but no specific investment targets had been identified yet as at the date of the 2018 Interim Report, i.e. 21 August 2018). The Board would like to provide additional information to the 2018 Annual Report and the 2019 Interim Report pursuant to paragraphs 11(8), 11A and 41A of Appendix 16 to the Listing Rules in relation to the use of the remaining net proceeds of approximately HKD186,439,000 raised from the Placing as follows:

	Planned use of proceeds from 1 July 2018 to 31 December 2019 HKD (approximately)	Actual use of proceeds from 1 July 2018 to 31 December 2018 HKD (approximately)	Actual use of proceeds from 1 January 2019 to 30 June 2019 HKD (approximately)	Unutilised proceeds as at 30 June 2019 HKD (approximately)
Repayment of bank loans	186,439,000	84,000,000	84,000,000	18,439,000
Total	<u>186,439,000</u>	<u>84,000,000</u>	<u>84,000,000</u>	<u>18,439,000</u>

As at 15 August 2019, the remaining portion of net proceeds of approximately HKD18,439,000 raised from the Placing had been used up by the Company for repayment of bank loans.

The above addition information does not affect other information contained in the 2018 Annual Report and the 2019 Interim Report and save as disclosed above, all other information in the 2018 Annual Report and the 2019 Interim Report remains unchanged.

By order of the Board
Consun Pharmaceutical Group Limited
AN Yubao
Chairman

Hong Kong, 31 October 2019

As at the date of this announcement, the Board comprises Mr. AN Yubao, Ms. LI Qian, Professor ZHU Quan and Mr. TANG Ning as executive Directors; Mr. SU Yuanfu, Mr. FENG Zhongshi and Ms. CHEN Yujun as independent non-executive Directors.